NO20081379L - Pankreatinmikropelletkjerner egnet for enterisk belegning - Google Patents

Pankreatinmikropelletkjerner egnet for enterisk belegning

Info

Publication number
NO20081379L
NO20081379L NO20081379A NO20081379A NO20081379L NO 20081379 L NO20081379 L NO 20081379L NO 20081379 A NO20081379 A NO 20081379A NO 20081379 A NO20081379 A NO 20081379A NO 20081379 L NO20081379 L NO 20081379L
Authority
NO
Norway
Prior art keywords
pancreatin
enteric coating
pancreatin micropellet
cores suitable
micropellet cores
Prior art date
Application number
NO20081379A
Other languages
English (en)
Inventor
Claus-Juergen Koelln
George Shlieout
Frithjof Sczesny
Jens Onken
Guido Ruesing
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081379(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO20081379L publication Critical patent/NO20081379L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er her beskrevet en fremgangsmåte for fremstilling og anvendelse av pankreatinmikropelletkjemer, og pankreatinmikropelletkjerner som lar seg erholde i henhold til denne fremgangsmåten, som er i det vesentlige fri for syntetiske oljer. Videre er det beskrevet enterisk belagte pankreatinmikropellets. Ved én utførelsesform er det tilveiebrakt et farmasøytisk preparat som omfatter en pankreatinmikropellet med et enterisk belegg som er utformet for å avlevere pankreatin til den øvre del av tarmen hos et pattedyr for frigivelse.
NO20081379A 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning NO20081379L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (1)

Publication Number Publication Date
NO20081379L true NO20081379L (no) 2008-05-14

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081379A NO20081379L (no) 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning

Country Status (15)

Country Link
EP (1) EP1931317B1 (no)
JP (1) JP5284092B2 (no)
KR (1) KR101302841B1 (no)
AT (1) ATE418329T1 (no)
AU (1) AU2006281415B2 (no)
CA (1) CA2619477C (no)
DE (1) DE602006004471D1 (no)
ES (1) ES2320174T3 (no)
IL (1) IL189457A (no)
MX (1) MX2008001557A (no)
NO (1) NO20081379L (no)
PL (1) PL1931317T3 (no)
PT (1) PT1931317E (no)
RU (1) RU2408364C2 (no)
WO (1) WO2007020260A2 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
KR101555058B1 (ko) 2005-07-29 2015-09-22 애보트 래버러토리즈 게엠베하 살균된 판크레아틴 분말의 제조방법
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
JP5966202B2 (ja) 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
WO2009083607A1 (en) * 2008-01-03 2009-07-09 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
ES2657673T3 (es) 2010-10-01 2018-03-06 Aptalis Pharma Limited Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) * 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
CA2920844A1 (en) 2013-08-09 2015-02-12 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
EP3215181B1 (en) 2014-11-05 2024-12-18 Abbott Laboratories GmbH Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
PH12022553091A1 (en) * 2020-06-10 2023-10-16 Kusum Healthcare Pvt Ltd Pharmaceutical composition of pancreatin
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102950325B1 (ko) 2024-01-26 2026-04-08 황준영 판크레아틴 함유 속방성 장용코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
BR0009012A (pt) * 1999-03-17 2001-12-26 Solvay Pharm Gmbh Medicamento para o tratamento de diabete
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
EP1931317A2 (en) 2008-06-18
PT1931317E (pt) 2009-02-02
KR20080034516A (ko) 2008-04-21
HK1119559A1 (en) 2009-03-13
EP1931317B1 (en) 2008-12-24
RU2408364C2 (ru) 2011-01-10
AU2006281415B2 (en) 2012-01-19
JP2009504710A (ja) 2009-02-05
JP5284092B2 (ja) 2013-09-11
RU2008109651A (ru) 2009-09-27
AU2006281415A1 (en) 2007-02-22
WO2007020260A2 (en) 2007-02-22
DE602006004471D1 (de) 2009-02-05
ATE418329T1 (de) 2009-01-15
CA2619477A1 (en) 2007-02-22
IL189457A (en) 2014-05-28
PL1931317T3 (pl) 2009-06-30
CA2619477C (en) 2015-05-26
KR101302841B1 (ko) 2013-09-02
IL189457A0 (en) 2008-06-05
MX2008001557A (es) 2008-02-15
ES2320174T3 (es) 2009-05-19
WO2007020260A3 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
NO20081379L (no) Pankreatinmikropelletkjerner egnet for enterisk belegning
NI201200072A (es) Métodos y composiciones para tratar cáncer
WO2010014949A3 (en) Compositions comprising hepatocyte-like cells and uses thereof
NO20084893L (no) Lyofiliserte terapeutiske peptistoffpreparater
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
WO2009055306A3 (en) Coating designs for the tailored release of dual drugs from polymeric coatings
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
EP2280720A4 (en) COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, PREPARATION AND APPLICATION METHOD
EP3914264A4 (en) DORSAL DERIVATIVE OLIGODENDROCYTE PROGENITORS FROM HUMAN PLURIPOTENTIC STEM CELLS
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
WO2008120105A3 (en) Pharmaceutical platform technology for the development of natural products
WO2016065323A3 (en) Single domain antibodies directed against intracellular antigens
WO2011156602A3 (en) Method, system, and composition for coloring zirconia dental ceramics
IL161903A0 (en) Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
TW200602089A (en) Sugar coatings and methods therefor
WO2007109605A3 (en) Pharmaceutical compositions
WO2011035062A3 (en) Spray dried human plasma
WO2014175917A8 (en) Multiparticulate l-menthol formulations and related methods
EP2264048A4 (en) PEPTID DES [ASP1] - [ALA1] -ANGIOTENSIN (1-7) -AGONIST AND PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF DISEASES
WO2009067543A3 (en) Treatment of histone deacetylase mediated disorders
DK2151235T3 (da) Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
EP1970099A3 (en) Process for relaxing or straightening hair
EP3735587A4 (en) SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC PROCEDURES
MA28563B1 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE